News
3 major takeaways from Novo Nordisk's Q1 earnings
Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations Yahoo Finance senior health reporter Anjalee Khemlani joins the Catlaysts team to share the biggest takeaways from the pharmaceutical giant's earnings,
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
22h
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy (semaglutide) intended for chronic weight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback